Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesQuest PharmaTech Inc

Quest PharmaTech Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.03 CAD 0.00(0%)
Last update at 2026-11-03T14:30:00Z
Market Cap
5.92M

Momentum Score

…

Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.03
Low
0.03
High
52 Week Price Range
0.03
Low
0.06
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Quest PharmaTech Inc (QPT.V) is limited; the company is listed on the TSX Venture Exchange and appears to be a small‑cap pharmaceutical/biotechnology issuer. Long-term growth may depend on successful product development, regulatory approvals, securing partnerships and additional financing, which could make the issuer of interest to investors seeking early-stage exposure to drug-development upside.
Material risks include limited disclosure and liquidity, high probability of needing new capital, development and regulatory uncertainty for therapeutic products, and meaningful dilution risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.03
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-0.42%
Net Debt
0.79M
ROCE
-3.82%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Type yearly yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Income before tax -1.80M -3.02M -7.33M -85.04M 190.06M
Minority interest - - - - 0.00M
Net income -1.80M -3.02M -7.33M -85.04M 190.06M
Selling general administrative 0.49M 0.77M 0.50M 0.62M 0.86M
Reconciled depreciation 0.00M 0.00M 0.01M 0.04M 0.04M
Ebit - - -0.83M -0.79M -1.07M
Ebitda - - -7.30M -84.99M 190.11M
Operating income -0.82M -1.32M -0.83M -0.79M -1.07M
Interest expense 0.02M 0.02M 0.02M 0.01M 0.01M
Tax provision 0.00M 0.00M - - -
Interest income - - - 0.00M 0.00M
Net interest income -0.02M -0.02M -0.02M -0.01M -0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 0.82M 1.32M 0.83M 0.79M 1.07M
Total other income expense net -0.96M -1.68M -6.48M -84.23M 191.14M
Net income from continuing ops -1.80M -3.02M -7.33M -85.04M 190.06M
Net income applicable to common shares - - -7.33M -85.04M 190.06M
Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Type yearly yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Total assets 22.56M 24.48M 84.36M 91.03M 175.61M
Total liab 1.17M 1.32M 1.11M 0.62M 0.39M
Total stockholder equity 21.40M 23.15M 83.25M 90.41M 175.22M
Common stock - - 30.74M 30.62M 30.62M
Capital stock 30.74M 30.74M 30.74M 30.62M 30.62M
Retained earnings -20.88M -19.08M 41.49M 48.78M 133.81M
Other assets - - 0.01M 0.01M 0.01M
Cash 0.21M 0.72M 0.37M 0.26M 0.20M
Total current liabilities 1.17M 1.32M 1.11M 0.62M 0.38M
Net debt 0.79M 0.28M 0.63M 0.24M 0.05M
Short long term debt 1.00M 1.00M 1.00M 0.50M 0.25M
Other stockholder equity - - -0.11M -0.05M -
Property plant equipment - - 0.00M 0.02M 0.06M
Total current assets 0.23M 0.84M 0.62M 0.29M 0.28M
Long term investments 22.33M 23.63M 83.72M 90.71M 175.27M
Net tangible assets - - 83.25M 90.41M 175.22M
Short term investments - - - - 0.00M
Net receivables - - 0.22M 0.00M 0.03M
Accounts payable - - 0.11M 0.11M 0.09M
Non current assets total 22.34M 23.64M 83.74M 90.74M 175.33M
Capital lease obligations - - 0.00M 0.01M 0.05M
Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Type yearly yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31 2021-01-31
Investments 0.00M 0.00M -0.01M -0.01M 0.30M
Change to liabilities - - 0.00M 0.02M -0.00M
Total cashflows from investing activities - - -0.01M -0.01M 0.26M
Net borrowings 0.00M 0.00M 0.50M 0.25M 0.25M
Total cash from financing activities 0.00M 0.68M 0.68M 0.25M 0.30M
Change to operating activities - - -0.23M 0.03M -0.03M
Net income -1.80M -3.02M -7.33M -85.04M 190.06M
Change in cash -0.51M 0.34M 0.11M 0.07M -1.95M
Begin period cash flow 0.72M 0.37M 0.26M 0.20M 2.15M
End period cash flow 0.21M 0.72M 0.37M 0.26M 0.20M
Total cash from operating activities -0.51M -0.34M -0.55M -0.17M -2.52M
Issuance of capital stock - 0.00M 0.09M 0.00M -
Depreciation 0.00M 0.00M 0.01M 0.04M 0.04M
Other cashflows from investing activities - - -0.01M -0.01M -0.04M
Change to account receivables - - - 0.03M -0.02M
Change to netincome - - 6.99M 84.75M -192.57M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.04M
Change in working capital -0.16M 0.25M -0.23M 0.08M -0.05M
Stock based compensation 0.08M 0.47M 0.15M 0.27M 0.45M
Other non cash items - - - - -13.54M
Free cash flow -0.51M -0.34M -0.55M -0.17M -2.55M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
QPT
Quest PharmaTech Inc		 -
-%		 0.03 - - 515.97 0.26 331.55 -0.16
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 - -
NRX
NurExone Biologic Inc.		 -0.01
1.96%		 0.50 - 6.90 - 15.26 - -7.24
MIR
MedMira Inc		 -
-%		 0.06 - - 223.37 - 293.42 -80.03
TTI
Thiogenesis Therapeutics Corp.		 0.01
1.59%		 0.64 - - - 15.17 - -58.16

Profile*

Quest PharmaTech Inc

Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.

97 Street NW, Edmonton, AB, Canada, T6E 5R9

780 448 1400

https://www.questpharmatech.com

Name Title Year Born
Dr. Ragupathy Madiyalakan Ph.D. CEO & Director NA
Mr. Pierre Vermette Chief Financial Officer NA
Mr. Roger Andrews Head of Investor Relations & Corp. Communications NA
Mr. Douglas C. Bachman VP of Corp. Devel. 1954
Mr. Thomas Woo VP of Product Devel. NA
Mr. Pierre Vermette C.A., CPA Chief Financial Officer NA
Mr. Roger Andrews Head of Investor Relations & Corporate Communications NA
Mr. Douglas C. Bachman Vice President of Corporate Development 1954
Mr. Thomas Woo Vice President of Product Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ORE
CAD 2.77
+8.86%
APM
CAD 4.95
+8.08%
NUAG
CAD 7.37
+8.06%
BZ
CAD 4.03
+8.04%
AYA
CAD 34.85
+7.96%
HUT
CAD 73.56
-17.26%
PHX
CAD 11.13
-12.22%
IVN
CAD 7.93
-10.70%
EFN
CAD 20.09
-10.39%
OBE
CAD 13.62
-6.71%

Equity Sectors*

  • Basic Materials

    +3.73%

  • Communication Services

    +1.16%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.14%

  • Energy

    -1.87%

  • Financial Services

    +1.53%

  • Healthcare

    +1.50%

  • Industrials

    +0.03%

  • Real Estate

    +0.71%

  • Technology

    +0.40%

  • Utilities

    +0.35%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…